About
Technology
Issues
FAQ
Links
Official Page
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.